Division of Cellular and Molecular Medicine, St. George's Hospital Medical School, London, UK.
Biotechnol Appl Biochem. 2011 Jan-Feb;58(1):58-67. doi: 10.1002/bab.6.
The number of approaches to recombinant protein production in plants is greater than ever before. Development of these new and improved technologies as production platforms for plant-made pharmaceuticals has and will continue to create new commercial opportunities in the pharmaceutical sector. However, it is inevitable that no single system will be optimal for the production of all recombinant proteins of interest in plants due to both the physical characteristics and the envisaged therapeutic application of each product. Here, we review a range of promising product/platform pairs emphasizing synergies during production and in clinical trials.
目前，植物中重组蛋白生产的方法比以往任何时候都多。这些新技术和改良技术作为植物制药的生产平台，已经并将继续在制药领域创造新的商业机会。然而，由于每个产品的物理特性和预期的治疗应用，没有一个单一的系统将是生产所有感兴趣的植物重组蛋白的最佳选择，这是不可避免的。在这里，我们回顾了一系列有前途的产品/平台对，强调了生产过程中和临床试验中的协同作用。
